The Efficacy Of Aprepitant Added To Ondansetron And Dexamethasone For Prevention Of Chemotherapy Induced Nausea And Vomiting (CINV) During Autologous Hematopoietic Stem Cell Transplantation (HSCT)  by Augustin, K.M. et al.
S190 Oral Presentations(Continued )2.4 C No or Poor Primary or
Secondary Review2.4 D Poor Data Correction
2.4 E Other Data related2.5 Poor Notification (Physician,
Tech, Participating Program,
Vendor etc)2.6 Other (Missed Review, No Review,
Inappropriate Release of
PHI, Data etc)3. Planned Deviation:
3.1 HCT/P Related:3.1 A Non-Conforming Product, as
Received3.1 B Non-Conforming to CPF Release
Criteria3.1 C Other
3.2 SOP related
4. Equipment or Supply related:
4.1 Recall or Notice
4.2 Calibration, Qualification or
Maintenance related
4.3 Alarm or Monitor System related
4.4 Other (Expired Lot, Out of Order or
Service, Inappropriate Use, etc)
5. Complaint:
5.1 Internal
5.2 External
6. Other:
6.1 Billing related
6.2 All Other92
DEVELOPMENT OF A DISTRIBUTED RESEARCH DATA MANAGEMENT
SYSTEM FOR A COMPUTERIZED PEDIATRIC HEMATOLOGY/ONCOLOGY
HEMATOPOIETIC STEM CELL TRANSPLANT REGISTRY – A COST EFFEC-
TIVE MODULAR APPROACH
Siddiqui, K.S.1, Mohammed, V.K.2, Belqaumi, A.F.3 1King Faisal Spe-
cialist Hospital & Research Centre, Riyadh, Central Province, Saudi Ara-
bia; 2King Faisal Specialist Hospital & Research Centre, Riyadh, Central
Province, Saudi Arabia; 3King Faisal Specialist Hospital & Research Cen-
tre, Riyadh, Central Province, Saudi Arabia
The role of a reliable data management and information system in
oncology services is well established. In addition to well-known risk
determining factors, the outcome of treatment efforts is also influ-
enced by the geography and genetic makeup of the population being
treated. The toxicity of the therapy used requires closemonitoring of
protocol outcomes to determine the risk benefit. Also advances in di-
agnostic tools and criteria, and identification of new risk factors re-
quire constant update of the data items being collected in such
a system.
Commercially available oncology data management and infor-
mation processing systems are not always useful in fulfilling
these requirements. The initial and maintenance costs for these
programs also make it less feasible for use in resource poor
countries.
Here we report our experience in the successful development
and implementation of a comprehensive, efficient and scalable
data management system specifically developed for hematopoietic
stem cell transplantation of patients with pediatric hematology/
oncology diseases. The data end-users (oncologists and trans-
planters) were critically involved with the system development
and data items incorporated were based on their recommenda-
tions. Ethnic and social characteristics (such as tribal affiliations),
which impact on disease genetics, were also included. The inte-
grated model allows for concentric expansion and linkages that
result in availability of data relating to multiple aspects of each pa-
tient’s care throughout his course, including pre- and post HSCT.
Changes in treatment protocols and diagnostic tests can be easily
incorporated as required. Policies and procedures were developedsimultaneously to direct the workings of this data management
system.
The simplicity, efficiency and scalability of the system design, and
its affordability makes it a model for use in other institutions, espe-
cially in developing countries.93
IMPLEMENTATION OF HEMATOLOGY-ONCOLOGY LECTURE SERIES FOR
HOUSESTAFF
Steinberg, A.S. Cedars-Sinai Medical Center, Los Angeles, CA
Background: We have a ward service dedicated to cancer patients.
Housestaff taking care of these patients includes three interns and
a fellow. There is also a consult service comprising a fellow, an in-
tern, and a resident. There is a need to implement formal, didactic,
teaching devoted to topics in hematology and oncology to improve
quality of care.
Objective: The development of a monthly lecture series for house-
staff rotating on a hematology-oncology rotation focusing on three
key areas:
a) Knowledge tomanage the patients on the hematology-oncology
service
b) What one is most likely to encounter in the practice of medi-
cine, regardless of eventual subspecialty field.
c) Relevance for Internal Medicine exams.
Methods: Topics chosen based on relevance included leukemia,
lymphoma, multiple myeloma, transplantation (these first four
comprising .75% of patients on service), coagulation, breast can-
cer, lung cancer, colon cancer, gynecological cancer, and pain
management/supportive care. Speakers included full-time faculty
as well as private physicians affiliated with the cancer center.
Emails and phone calls were placed to the physicians and an-
nouncements made at division meetings and schedules developed.
Test questions were given to housestaff at the start of their one
month rotation and at the end of rotation. Lectures were sched-
uled for afternoons if possible to avoid conflicts with morning
rounds. Occasional morning talks were necessary however due
to schedule issues. Format of lectures was flexible (power point,
dry-eraser board).
Results:Overall feedback was positive for the lectures. The two con-
ditions affecting optimal success of the program concerned schedul-
ing, including housestaff schedules and availability of when and
which speakers could lecture. The question/answer testing is early
in the process.
Conclusion: A didactic lecture series is an important aspect of stem
cell hematology-oncology education for housestaff and will improve
quality of care of the stem cell transplant service. Repeating lectures
every month is a challenge for several reasons. Possible interventions
in the future may include:
a) Focusing lecturing duties to full-time faculty, with an emphasis
on faculty currently on service
b) Creating power point presentations and handouts on file for use
by multiple people so that rotating faculty may use these materials
for talks
c) Statistical analysis of scores from pre-rotation and post-rotation
exams to assess housestaff performancePHARMACY ORAL
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THE EFFICACY OF APREPITANT ADDED TO ONDANSETRON AND DEXA-
METHASONE FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA
AND VOMITING (CINV) DURING AUTOLOGOUS HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT)
Augustin, K.M.1, Hladnik, L.M.1, Dietz, R.2, Gabriel, J.3, Vij, R.3,
Cashen, A.F.3, Stockerl-Goldstein, K.3, Abboud, C.N.3, Nobbe, J.A.1,
Gao, F.4, DiPersio, J.F.3 1Barnes Jewish Hospital, St. Louis, MO;
2Barnes Jewish Hospital, St. Louis, MO; 3Washington University,
St. Louis, MO; 4Washington University, St. Louis, MO
Despite premedication with dexamethasone and ondansetron,
acute and delayed CINV remains a persistent problem in the set-
ting of autologous HSCT. Aprepitant is an oral neurokinin-1
Oral Presentations S191antagonist approved for the prevention of acute and delayed CINV
associated with initial and repeat courses of moderately and highly
emetogenic chemotherapy in combination with other antiemetics.
We evaluated the outcomes of ondansetron and dexamethasone
compared with aprepitant, ondansetron, and dexamethasone in pa-
tients undergoing autologous HSCT, with BEAM or Melphalan
conditioning, in a randomized single center clinical trial. Patients
were randomized to receive either ondansetron and dexamethasone
on the days of chemotherapy followed by 3 days of dexamethasone
(OD) or OD combined with aprepitant 125 mg on the first day of
conditioning, followed by aprepitant 80 mg daily until day
0 (AOD). Rescue antiemetics were allowed. Acute phase was
defined as each day (24-hr period) of chemotherapy. Delayed phase
was defined as the 5 days (0 – 120 hrs) following the last dose of
chemotherapy. Complete response (CR) was defined as no emesis
or rescue antiemetics in a 24-hour period. Major response (MaR)
was defined as 1 episode of emesis or the need for rescue anti-
emetics in a 24-hour period. Twenty-four patients were random-
ized to each arm. Age, gender, prior history of CINV, and
conditioning regimen were similar between OD and AOD. There
were no significant differences between the two arms in the rates
of acute or delayed nausea, CR, and MaR (Table 1). Despite pre-
medication, almost all of the patients experienced nausea and/or
vomiting after the completion of the study period up to day +30
(OD 100% and AOD 83.3%; p5 0.11). Grade 3/4 nonhematologic
toxicity was similar between the two groups. The most common
toxicities reported were nausea, hypophosphatemia, anorexia, and
infection. Although the CR rates for acute and delayed emesis
were greater in AOD, the addition of aprepitant did not signifi-
cantly improve CINV control in this small autologous HSCT
population.Table 1. Antiemetic Response Rates
OD (%) n5 24 AOD (%) n5 24Table 1.
Mean pK values (6SD
Cmaxmg/L)
Tmax (h)
C0 (mg/L)
Css (mg/L)
AUC0-6 (mgh/L)
CLss (L/hkg)
Vss (L/kg)
T1/2 (h)) Day 11 (N5
15.76 23
1.976 0.4
0.316 0.3
5.576 7.7
32.86 46
1.806 1.1
3.606 2.0
0.946 0.6IV MMF Adm
18) Day 17 (N
.6 12.16 5
4 1.986 0
3 0.686 0
4 4.846 2
.4 27.46 1
0 1.486 0
4 3.606 1
4 1.386 1Acute Nausea 25 25 p5 1.0
Delayed Nausea 87.5 87.5 p5 1.0
Acute Phase
CR 62.5 75 p5 0.53
MaR 37.5 25
Delayed Phase
CR 8.3 16.7 p5 0.47
MaR 62.5 66.7
Other 29.2 16.695
PHARMACOKINETICS OF MYCOPHENOLATE MOFETIL (MMF) IN COMBI-
NATION WITH TACROLIMUS IN PEDIATRIC ALLOGENEIC STEM CELL
TRANSPLANT (ALLOSCT) RECIPIENTS# 12 YEARS OF AGE
Militano, O.1, Bhatia, M.1, Figurski, M.2, Shaw, L.2, Geyer, M.B.1,
Jacobson, J.S.3, Morris, E.1, Satwani, P.1, George, D.1, Garvin, J.H.1,
Cairo, M.S.1,4,5 1Morgan Stanley Children’s Hospital, New York-Presby-
terian, Columbia University, NY; 2University of Pennsylvania, Philadel-inistration
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.61
.16
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.16phia, PA; 3Columbia University, New York, NY; 4Columbia University,
New York, NY; 5Columbia University, New York, NY
Background:The optimal dosing of MMF in pediatric AlloSCT re-
cipients is unknown.
Objective: To determine MMF PK in pediatric AlloSCT recipi-
ents\12 years of age.
Methods:GVHDprophylaxis included tacrolimusDay –1 (5-20 ng/
mL) and MMF 900 mg/m2 IV Q6H starting on Day +1, then con-
verted to PO (same dose) after Day +14. MPA serum samples were
drawn on Days +1, +7, +14 (IV phase) and twice between Day +45-
+100 (PO phase) at hour 0, 0.5, 1, 2, 3, 4, 6 post-dose. MPA plasma
concentrations were determined by reverse-phase HPLC and LC/
MS/MS. Non-compartmental PK analysis of total MPA was
performed.
Results: PK was completed in 25 pts: mean age 5 yrs; M:F 12:13;
14 pts\6 yrs & 11 pts 6-12 yrs; 11 pts non-malignant & 14 with
malignant disease; 14 pts received unrelated AlloSCT. Patients
with non-malignant disease received reduced-intensity condition-
ing. Median time to myeloid and platelet engraftment was 21
and 33 days, respectively. KM probability of Grade II-IV acute
GVHD (aGVHD) and limited + extensive chronic GVHD was
52% and 39.8%, respectively. Probability of 1 year OS was
78.8% (CI95: 62%-95%). There was a significant inter- and intra-
patient variability in AUC0-6 and MPA trough (C0) (Table 1).
There was no significant difference in MMF PK between
pts\6 vs 6-12 yrs of age following IV or PO MMF administra-
tion. Univariate analyses did not find a correlation between
AUC, C0 or Css on Days 7 or 14 and risk of aGVHD. There
was a significant [ in MPA trough on day 7 vs 1 (P5 0.009),
[AUC on day 14 vs 7 (P5 0.049) and Y Vss day 14 vs day 1 &
7 (P5 0.001). There was also a significant [ T1/2 on day 45 vs
day 1 and 7 (P5 0.043 and P5 0.042, respectively) as well as [
CLss and Vss on day 45 vs day 14 (P5 0.01 for CLss and
P5 0.006 for Vss).
Conclusion: This change in PK parameters with time could be due
to improved mucosal healing following conditioning that leads to
improved drug absorption and enterohepatic recirculation. Based
on these results, we recommend reducing MMF dose to 600-
900 mg/m2 q8 h in the early post-transplant period in children
\12 yrs of age to target Css5 2.5-5 mg/L (Nash et al, BBMT
2005).96
EVALUATION OF THE INITIAL DOSE CALCULATION OF INTRAVENOUS BU-
SULFAN (BUSULFEX) IN ADULTS RECEIVING A CONVENTIONAL BU/
CY2 ALLOGENEIC PREPARATIVE REGIMEN
O’Neal, N.K., DuBois, L.K., Williams, C.B., Casey, K.L., Aljitawi, O.S.,
Ganguly, S., Abhyankar, S., McGuirk, J.P. The University of Kansas
Hospital, Kansas City, KS
Several studies have reported that the variability in pharmacoki-
netic (PK) parameters after intravenous busulfan dosing is signifi-
cantly lower than that recorded after dosing with the oral
formulation. However, other published experiences have concluded
that both the oral and intravenous formulation of busulfan yield wide
interpatient variability in PK parameters.MMF PO 1st sample MMF PO 2nd sample
y 114 (N5 23) Day 145-100 (N5 13) Day 145-100 (N5 7)
17.86 15.2 13.46 12.8 13.56 8.4
1.876 0.34 1.656 1.05 1.366 0.85
0.686 0.64 1.396 1.44 1.666 1.48
6.356 3.11 5.006 3.46 7.226 3.70
36.66 18.6 26.46 20.6 27.456 16.0
1.306 0.63 2.326 1.42 1.616 1.02
3.006 1.02 10.436 8.99 21.226 38.25
1.256 1.02 2.986 2.38 12.786 20.58
